168 related articles for article (PubMed ID: 10953035)
1. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene.
Gu JJ; Stegmann S; Gathy K; Murray R; Laliberte J; Ayscue L; Mitchell BS
J Clin Invest; 2000 Aug; 106(4):599-606. PubMed ID: 10953035
[TBL] [Abstract][Full Text] [Related]
2. Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice.
Gu JJ; Tolin AK; Jain J; Huang H; Santiago L; Mitchell BS
Mol Cell Biol; 2003 Sep; 23(18):6702-12. PubMed ID: 12944494
[TBL] [Abstract][Full Text] [Related]
3. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression.
Dayton JS; Lindsten T; Thompson CB; Mitchell BS
J Immunol; 1994 Feb; 152(3):984-91. PubMed ID: 7905505
[TBL] [Abstract][Full Text] [Related]
4. Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation.
Zimmermann AG; Gu JJ; Laliberté J; Mitchell BS
Prog Nucleic Acid Res Mol Biol; 1998; 61():181-209. PubMed ID: 9752721
[TBL] [Abstract][Full Text] [Related]
5. Immune Response-Dependent Assembly of IMP Dehydrogenase Filaments.
Calise SJ; Abboud G; Kasahara H; Morel L; Chan EKL
Front Immunol; 2018; 9():2789. PubMed ID: 30555474
[TBL] [Abstract][Full Text] [Related]
6. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor.
Jain J; Almquist SJ; Heiser AD; Shlyakhter D; Leon E; Memmott C; Moody CS; Nimmesgern E; Decker C
J Pharmacol Exp Ther; 2002 Sep; 302(3):1272-7. PubMed ID: 12183689
[TBL] [Abstract][Full Text] [Related]
7. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
Jayaram HN; Cooney DA; Grusch M; Krupitza G
Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
[TBL] [Abstract][Full Text] [Related]
8. Inosine-5'-monophosphate dehydrogenase is required for mitogenic competence of transformed pancreatic beta cells.
Metz S; Holland S; Johnson L; Espling E; Rabaglia M; Segu V; Brockenbrough JS; Tran PO
Endocrinology; 2001 Jan; 142(1):193-204. PubMed ID: 11145582
[TBL] [Abstract][Full Text] [Related]
9. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes.
Jain J; Almquist SJ; Ford PJ; Shlyakhter D; Wang Y; Nimmesgern E; Germann UA
Biochem Pharmacol; 2004 Feb; 67(4):767-76. PubMed ID: 14757177
[TBL] [Abstract][Full Text] [Related]
10. A putative role for inosine 5' monophosphate dehydrogenase (IMPDH) in Leishmania amazonensis programmed cell death.
Pitaluga AN; Moreira ME; Traub-Csekö YM
Exp Parasitol; 2015 Feb; 149():32-8. PubMed ID: 25499513
[TBL] [Abstract][Full Text] [Related]
11. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent.
Jain J; Almquist SJ; Shlyakhter D; Harding MW
J Pharm Sci; 2001 May; 90(5):625-37. PubMed ID: 11288107
[TBL] [Abstract][Full Text] [Related]
12. T cell activation triggers reversible inosine-5'-monophosphate dehydrogenase assembly.
Duong-Ly KC; Kuo YM; Johnson MC; Cote JM; Kollman JM; Soboloff J; Rall GF; Andrews AJ; Peterson JR
J Cell Sci; 2018 Sep; 131(17):. PubMed ID: 30154209
[TBL] [Abstract][Full Text] [Related]
13. Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias.
Nagai M; Natsumeda Y; Konno Y; Hoffman R; Irino S; Weber G
Cancer Res; 1991 Aug; 51(15):3886-90. PubMed ID: 1677309
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte counts in kidney allograft recipients are associated with IMPDH2 3757T>C gene polymorphism.
Pazik J; Ołdak M; Podgórska M; Lewandowski Z; Sitarek E; Płoski R; Szmidt J; Chmura A; Durlik M; Malejczyk J
Transplant Proc; 2011 Oct; 43(8):2943-5. PubMed ID: 21996196
[TBL] [Abstract][Full Text] [Related]
15. Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5' palindromic octamer sequence.
Zimmermann AG; Wright KL; Ting JP; Mitchell BS
J Biol Chem; 1997 Sep; 272(36):22913-23. PubMed ID: 9278455
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate.
Wang W; Papov VV; Minakawa N; Matsuda A; Biemann K; Hedstrom L
Biochemistry; 1996 Jan; 35(1):95-101. PubMed ID: 8555204
[TBL] [Abstract][Full Text] [Related]
17. Induction of Tmolt4 leukemia cell death by 3,3-disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2-4-diones: specificity for type II inosine 5'-monophasphate dehydrogenase.
Barnes BJ; Izydore RA; Eakin AE; Hall IH
J Pharmacol Exp Ther; 2001 Aug; 298(2):790-6. PubMed ID: 11454943
[TBL] [Abstract][Full Text] [Related]
18. The CBS subdomain of inosine 5'-monophosphate dehydrogenase regulates purine nucleotide turnover.
Pimkin M; Markham GD
Mol Microbiol; 2008 Apr; 68(2):342-59. PubMed ID: 18312263
[TBL] [Abstract][Full Text] [Related]
19. Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases.
Ratcliffe AJ
Curr Opin Drug Discov Devel; 2006 Sep; 9(5):595-605. PubMed ID: 17002220
[TBL] [Abstract][Full Text] [Related]
20. Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells.
Dubsky PC; Friedl J; Stift A; Bachleitner-Hofmann T; Jakesz R; Gnant MF; Weigel G
Clin Chim Acta; 2006 Feb; 364(1-2):139-47. PubMed ID: 16051207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
